Gilead Sciences (NASDAQ: GILD ) reports earnings on July 23. According to Bloomberg, analysts are estimating over $2.8 billion in sales. But remember that analysts were off -- off by a lot! -- last quarter in guessing sales, with Gilead's $2.3 billion in Sovaldi sales crushing their expectations. Could Gilead surprise to the upside again? Watch the video below for our take.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.